SEARCH:   Advanced

Blood, 1 September 2006, Vol. 108, No. 5, pp. 1569-1570. Prepublished online as a Blood First Edition Paper on April 27, 2006; DOI 10.1182/blood-2006-03-009548. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-009548v1 108/5/1569    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mazzolai, L. Articles by Duchosal, M. A Search for Related Content PubMed PubMed Citation Articles by Mazzolai, L. Articles by Duchosal, M. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 13, 2006 Accepted April 18, 2006 Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy Lucia Mazzolai*, Patrick Hohlfeld, Francois Spertini, Daniel Hayoz, Marc Schapira, and Michel A Duchosal Vascular Medicine, University Hospital of Lausanne (CHUV), Switzerland Obstetrics, University Hospital of Lausanne (CHUV), Switzerland Immunology and Allergy, University Hospital of Lausanne (CHUV), Switzerland Hematology of the University Hospital of Lausanne (CHUV), Switzerland * Corresponding author; email: lucia.mazzolai{at}chuv.ch. Heparin is the drug of choice for the treatment or the prevention of thromboembolic disease during pregnancy. However, treatment options are limited when heparin cannot be used because of hypersensitivity skin reactions. Despite the recent availability of new anticoagulant agents, data relating to their use during pregnancy is lacking. This report describes the successful management with fondaparinux, during 150 days, of a pregnant patient with protein S deficiency and prior DVT who developed heparin and danaparoid hypersensitivity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Schindewolf, S. Schwaner, M. Wolter, H. Kroll, A. Recke, R. Kaufmann, W.-H. Boehncke, E. Lindhoff-Last, and R. J. Ludwig Incidence and causes of heparin-induced skin lesions Can. Med. Assoc. J., October 13, 2009; 181(8): 477 - 481. [Abstract] [Full Text] [PDF] A. H. James Venous Thromboembolism in Pregnancy Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 326 - 331. [Abstract] [Full Text] [PDF] P. S. GIBSON and R. POWRIE Anticoagulants and pregnancy: When are they safe? Cleveland Clinic Journal of Medicine, February 1, 2009; 76(2): 113 - 127. [Abstract] [Full Text] [PDF] T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF] S. M. Bates, I. A. Greer, I. Pabinger, S. Sofaer, and J. Hirsh Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 844S - 886S. [Abstract] [Full Text] [PDF] S. M. Bates Management of Pregnant Women with Thrombophilia or a History of Venous Thromboembolism Hematology, January 1, 2007; 2007(1): 143 - 150. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020